Search results for "Density"

showing 10 items of 4402 documents

Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits

2003

Objective— The effects of combined expression of human hepatic lipase (HL) and human apolipoprotein B (apoB) on low-density lipoprotein (LDL) subclasses were examined in rabbits, a species naturally deficient in HL activity. Methods and Results— In apoB-transgenic rabbit plasma, >80% of the protein was found in the 1.006- to 1.050-g/mL fraction. Gradient gel electrophoresis (GGE) of this fraction revealed two distinct species, designated large and small LDL. A denser fraction (d=1.050 to 1.063 g/mL) contained small LDL as well as another discrete LDL subspecies, designated very small LDL. Expression of HL resulted in reductions in protein concentrations in the 1.006- to 1.050-g/mL densi…

medicine.medical_specialtyApolipoprotein BRecombinant Fusion ProteinsTriacylglycerol lipaseAnimals Genetically ModifiedSpecies SpecificityInternal medicineCentrifugation Density GradientmedicineAnimalsHumansTriglyceridesApolipoproteins BGel electrophoresischemistry.chemical_classificationLagomorphabiologyLipasebiology.organism_classificationAnimal FeedSpecific Pathogen-Free OrganismsLipoproteins LDLMolecular WeightEndocrinologyEnzymechemistrybiology.proteinElectrophoresis Polyacrylamide GelFemalelipids (amino acids peptides and proteins)Density gradient ultracentrifugationRabbitsHepatic lipaseCardiology and Cardiovascular MedicineLipoprotein
researchProduct

How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL

2017

Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cholesterol (LDL-C) through a statin therapy is a gold standard in the management of patients with dyslipidaemia and cardiovascular disease (CVD). However, even when LDL-C levels are at or below clinically recommended target levels, residual cardiovascular (CV) risk still remains. Therefore, assessing lipoproteins beyond LDL-C in managing CV risk is imperative. Methods: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a nu…

medicine.medical_specialtyApolipoprotein BType 2 diabetes030204 cardiovascular system & hematologyRisk AssessmentTriglyceride03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoprotein cholesterolRisk FactorsInternal medicinemedicineInternal MedicineHumans030212 general & internal medicineAtherogenic dyslipidaemiaHypolipidemic AgentsbiologyCholesterolbusiness.industryDisease Managementnutritional and metabolic diseasesGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCardiovascular diseaseCardiovascular riskResidual riskNon-high-density lipoprotein cholesterolEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessmentCardiology and Cardiovascular MedicineApolipoprotein BBiomarkersLipoproteinLipoprotein(a)
researchProduct

An evaluation of RVX-208 for the treatment of atherosclerosis

2015

Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Resverlogix Corporation (Calgary, AB, Canada). It acts through an epigenetic mechanism by inhibiting the bromodomain and extraterminal (BET) family of proteins, increasing apolipoprotein A-I (apoA-I) and targeting high-density lipoprotein (HDL) metabolism, including generating of nascent HDL and increased larger HDL particles, resulting in the stimulation of reverse cholesterol transport. RVX-208 also has a beneficial effect on inflammatory factors known to be involved in atherosclerosis and plaque stability. New therapeutic strategies are needed for patients with atherosclerosis.Areas covered: …

medicine.medical_specialtyApolipoprotein Bapolipoprotein A-IRVX 208high-density lipoproteinPharmacologyEpigenesis Geneticchemistry.chemical_compoundatherosclerosiHigh-density lipoproteinMetabolic DiseasesInternal medicinemedicineAnimalsHumansPharmacology (medical)QuinazolinonesPharmacologybiologyAnimalCholesterolMedicine (all)Cholesterol HDLReverse cholesterol transportRVX-208QuinazolineGeneral MedicineAtherosclerosisPlaque AtheroscleroticMetabolic DiseaseBromodomainOrally activeEndocrinologyhigh-density lipoprotein particlechemistryQuinazolinesbiology.proteinlipids (amino acids peptides and proteins)HumanLipoproteinExpert Opinion on Investigational Drugs
researchProduct

From Menace to Marvel

2009

Diabetes mellitus is a major risk factor for cardiovascular disease, and its prevalence is suspected to further increase in the coming years in the Western hemisphere and also in countries with emerging economies, like India, China, and Brazil. Together with the increasing prevalence of obesity and metabolic syndrome and the subsequent development of arterial hypertension, the epidemic of adiposity and diabetes mellitus may eat up most of the improvement of cardiovascular outcomes that we have seen within the last decades.1 The risk of atherosclerosis is inversely related to circulating levels of high-density lipoprotein (HDL) cholesterol. Results from the Framingham Study demonstrated that…

medicine.medical_specialtyApolipoprotein BbiologyCholesterolbusiness.industryReverse cholesterol transportTorcetrapibnutritional and metabolic diseasesmedicine.diseaseAngiotensin IIchemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineInternal Medicinemedicinebiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessLipoproteinHypertension
researchProduct

Review and update on drugs related to the development of osteonecrosis of the jaw

2019

Conflict of interest Conclusions of the working group on “New drugs related to the de-velopment of osteonecrosis of the jaw”. Spanish Society of Cranio-mandibular Dysfunction and Orofacial Pain and Spanish Society of Oral Medicine SEDCYDO-SEMO joint International Meeting: 30th SEDCYDO annual meeting & 15th SEMO Congress. Bilbao (Spain); June, 2019. [EN] Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of cer-tain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or a…

medicine.medical_specialtyBevacizumabReviewMRONJ03 medical and health sciencesantiresorptives0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectGeneral DentistrybisphosphonatesAfliberceptBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industrySunitinibOsteonecrosis030206 dentistryEvidence-based medicinemedicine.disease:CIENCIAS MÉDICAS [UNESCO]osteonecrosis of the jawantiangiogenicsDenosumabOtorhinolaryngologyPharmaceutical PreparationsUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism

2000

To induce dietary atherosclerosis in mice, high-fat/high-cholesterol (HF) diets are frequently supplemented with cholic acid (CA). This diet produces low plasma levels of high-density lipoprotein (HDL) and high levels of low-density lipoprotein (LDL). However, HF diets without any added CA, which more closely resemble human diets, increase levels of both HDL and LDL, suggesting that CA may be responsible for the lowering of HDL. Our aim was to examine the potential mechanism responsible for the lowering of HDL. Nontransgenic (NTg) C57BL mice and apoA-I-transgenic (apoAI-Tg) mice, with greatly increased basal apoA-I and HDL levels, were used. Mice were fed the following four diets: control (…

medicine.medical_specialtyBile acidmedicine.drug_classCholesterolResponse elementCholic acidnutritional and metabolic diseasesBiologyBiochemistrychemistry.chemical_compoundEndocrinologyHigh-density lipoproteinchemistryInternal medicineLow-density lipoproteinpolycyclic compoundsmedicinelipids (amino acids peptides and proteins)Hepatic lipaseLipoproteinEuropean Journal of Biochemistry
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Differential effects of sex hormones on peri- and endocortical bone surfaces in pubertal girls.

2005

Context: The role of sex steroids in bone growth in pubertal girls is not yet clear. Bone biomarkers are indicators of bone metabolic activity, but their value in predicting bone quality has not been studied in growing girls. Objective: This study examines the association of sex hormones and bone markers with bone geometry and density in pubertal girls. Design: The study was designed as a 2-yr longitudinal study in pubertal girls. Measurements were performed at baseline and at 1and 2-yr follow-ups. Setting: The study was conducted in a university laboratory. Participants: A total of 258 10- to 13-yr-old healthy girls at the baseline participated. Methods:Peripheralquantitativecomputedtomogr…

medicine.medical_specialtyBone densityAdolescentEndocrinology Diabetes and MetabolismClinical BiochemistryLong boneAcid PhosphataseOsteocalcinContext (language use)BiochemistryBone resorptionEndocrinologySex hormone-binding globulinBone DensityInternal medicineSex Hormone-Binding GlobulinmedicineHumansTestosteroneChildGonadal Steroid HormonesBone growthBone mineralMenarcheBone DevelopmentbiologyEstradiolTibiabusiness.industryTartrate-Resistant Acid PhosphataseBiochemistry (medical)PubertyAlkaline PhosphataseIsoenzymesmedicine.anatomical_structureEndocrinologyOsteocalcinbiology.proteinLinear ModelsFemalebusinessBiomarkersThe Journal of clinical endocrinology and metabolism
researchProduct

Impact of estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model.

2014

Objective The common inflammatory pathophysiology has nourished the hypothesis of a relationship between osteoporosis and cardiovascular disease. Estrogens are key agents in the modulation of both processes. We investigated whether induction of atherosclerosis affects bone and whether estrogens modulate both processes. Methods Female apolipoprotein E-deficient mice (a well-established model of atherogenesis) were ovariectomized or falsely operated and fed either standard diet or high-fat diet (HFD). Six animals were included in each of the four groups. To clarify mechanisms, we treated preosteoblastic MC3T3-E1 cells with mouse serum. Results Physiological levels of estrogens in falsely oper…

medicine.medical_specialtyBone densityApolipoprotein BOvariectomyOsteoporosisDiet High-FatBone resorptionMiceApolipoproteins EBone DensityTrabecular PatternInternal medicinemedicineAnimalsHumansBone ResorptionBone mineralbiologybusiness.industryObstetrics and GynecologyEstrogensmedicine.diseaseAtherosclerosisDisease Models AnimalEndocrinologymedicine.anatomical_structureOvariectomized ratbiology.proteinOsteoporosisCortical boneFemalebusinessMenopause (New York, N.Y.)
researchProduct

Association between low-frequency ultrasound and hip fractures - comparison with DXA-based BMD

2013

Background New methods for diagnosing osteoporosis and evaluating fracture risk are being developed. We aim to study the association between low-frequency (LF) axial transmission ultrasound and hip fracture risk in a population-based sample of older women. Methods The study population consisted of 490 community-dwelling women (78–82 years). Ultrasound velocity (VLF) at mid-tibia was measured in 2006 using a low-frequency scanning axial transmission device. Bone mineral density (BMD) at proximal femur measured using dual-energy x-ray absorptiometry (DXA) was used as the reference method. The fracture history of the participants was collected from December 1997 until the end of 2010. Lifestyl…

medicine.medical_specialtyBone densityCortical boneOsteoporosisPopulationDentistryRisk AssessmentHip fractureAbsorptiometry PhotonRheumatologyBone DensityPredictive Value of TestsRisk FactorsmedicineHumansOrthopedics and Sports MedicineProspective StudieseducationOsteoporosis PostmenopausalAgedUltrasonographyFemoral neckAged 80 and overBone mineralHip fractureeducation.field_of_studyTibiaFemur NeckHip Fracturesbusiness.industryOdds ratiomedicine.diseaseFractures Spontaneousmedicine.anatomical_structureSpeed of soundOsteoporosisFemaleRadiologybusinessRisk assessmentQuantitative ultrasoundFollow-Up StudiesResearch ArticleBMC Musculoskeletal Disorders
researchProduct